Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 601–700 of 1,002
Reichardt, W., Dürr, C., von Elverfeldt, D., Jüttner, E., Gerlach, U. V., Yamada, M., Smith, B., Negrin, R. S., & Zeiser, R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4770 · Cited by 88
Hymes, S. R., Alousi, A. M., & Cowen, E. W. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.11.961 · Cited by 95
Advantages and clinical applications of natural killer cells in cancer immunotherapy
Ames, E., & Murphy, W. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1469-8 · Cited by 100
“[34] first identified a correlation between donor KIR and host KIR ligand expression in tumor relapse occurrence.”
BackgroundAl‐Attar, A., Presnell, S. R., Peterson, C. A., Thomas, D. T., & Lutz, C. T. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.04.001 · Cited by 93
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 88
“NK cells play also a critical role in autologous stem cell transplantation in several hematological malignancies, as described in the section [5-10].”
BackgroundBispecific Antibodies for the Treatment of Acute Myeloid Leukemia
Guy, D. G., & Uy, G. L. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0472-8 · Cited by 97
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
Liao, D., Wang, M., Liao, Y., Li, J., & Niu, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00609 · Cited by 91
Locatelli, F., Lucarelli, B., & Merli, P. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.852537 · Cited by 102
“demonstrated that, in the setting of haploidentical transplantation, NK alloreactivity protects not only against GvHD and acute myeloid leukemia relapse, but also against rejection [113].”
BackgroundCampana, D., & Leung, W. H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12358 · Cited by 96
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 103
“Mismatch of the KIR ligand of allogeneic hematopoietic stem cell transplants has been associated with increased graft-versus-leukemia effect in cases of acute myelogenous leukemia (AML), presumably because the donor NK cells are not inhibited by native MHC Class I molecules on the tumor cells.(12) While encouraging, t…”
ResultMoroso, V., Metselaar, H. J., Mancham, S., Tilanus, H. W., Eissens, D., van der Meer, A., van der Laan, L. J. W., Kuipers, E. J., Joosten, I., & Kwekkeboom, J. (2010) · Liver Transplantation · doi:10.1002/lt.22080 · Cited by 92
“Upon experimental allogeneic bone marrow transplantation donor-derived NK cells protect against graft rejection by killing recipient T cells and antigen presenting cells.(26) We propose that a similar mechanism may be effective after LTX.”
BackgroundMethodInfluentialLoss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
Momi, S., Falcinelli, E., Giannini, S., Ruggeri, L., Cecchetti, L., Corazzi, T., Libert, C., & Gresele, P. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090687 · Cited by 89
“…remaining cells were washed twice with PBS. Finally, bone marrow cells were resuspended at a final concentration of 20 × 106 cells per ml in PBS and, the day after total body irradiation, 10 × 106 cells/mouse were injected into recipient mice i.v. via the lateral tail vein (Ruggeri et al., 2002).”
MethodSelf-citationNKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
Siemaszko, J., Marzec-Przyszlak, A., & Bogunia‐Kubik, K. (2021) · Cells · doi:10.3390/cells10061420 · Cited by 97
Childhood acute myeloid leukaemia
Rubnitz, J. E., & Inaba, H. (2012) · British Journal of Haematology · doi:10.1111/bjh.12040 · Cited by 104
“The powerful antileukaemic effect of KIR-mismatched donor natural killer (NK) cells in the setting of allogeneic HSCT, first demonstrated by Ruggeri et al (2002), has been observed in AML patients who undergo HSCT in first remis- sion and after relapse (Giebel et al, 2003; Ruggeri et al, 2007).”
BackgroundInamoto, Y., Flowers, M. E. D., Lee, S. J., Carpenter, P. A., Warren, E. H., Deeg, H. J., Storb, R. F., Appelbaum, F. R., Storer, B. E., & Martin, P. J. (2011) · Blood · doi:10.1182/blood-2011-01-330217 · Cited by 87
NK cell receptors and their ligands in leukemia
Verheyden, S. J., & Demanet, C. (2007) · Leukemia · doi:10.1038/sj.leu.2405040 · Cited by 88
Expanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 96
“Generally, allogeneic NK cells do not cause graftversus-host disease (GvHD) [31,37,78], but it was recently reported that this had occurred after administration of expanded donor NK cells to patients who had received a previous allogeneic hematopoietic stem cell transplant, probably because of activation ofT cell allo…”
BackgroundIFN-γ Acts on T Cells to Induce NK Cell Mobilization and Accumulation in Target Organs
Wald, O., Weiss, I. D., Wald, H., Shoham, H., Bar-Shavit, Y., Beider, K., Galun, E., Weiss, L., Flaishon, L., Shachar, I., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4716 · Cited by 99
“The use of delayed lymphocyte infusion after allogeneic BMT resulted in less graft-vshost disease with a significant graft-vs-leukemia response (11, 12).”
BackgroundCord Blood as a Source of Natural Killer Cells
Mehta, R. S., Shpall, E. J., & Rezvani, K. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2015.00093 · Cited by 91
“They are the first cells to reconstitute after HSCT (8–14), they facilitate engraftment (78), they do not cause GVHD, and they may even prevent this complication by eliminating host antigen-presenting cells and donor alloreactive T cells (83, 123).”
BackgroundMethodType 1 Innate Lymphoid Cell Biology: Lessons Learnt from Natural Killer Cells
Jiao, Y., Huntington, N. D., Belz, G. T., & Seillet, C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00426 · Cited by 85
“Alloreactive NK cells reduce GVHD by eliminating recipient antigen-presenting cells that drive immune cell activation (62).”
BackgroundClausen, J., Wolf, D. G. F., Petzer, A. L., Gunsilius, E., Schumacher, P., Kircher, B., Gastl, G. A., & Nachbaur, D. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03360.x · Cited by 86
Dendritic Cell-NK Cell Cross-Talk: Regulation and Physiopathology
Zitvogel, L., Terme, M., Borg, C., & Trinchieri, G. (2005) · Springer eBooks · doi:10.1007/3-540-27743-9_8 · Cited by 94
“marrow transplantation may be used to enhance engraftment and to prevent leukemia relapse by boosting graft-versus-leukemia effects without augmenting the risk of developing graft-versus-host disease [88].”
BackgroundRizzieri, D. A., Storms, R. W., Chen, D., Long, G. D., Yang, Y., Nikcevich, D. A., Gasparetto, C., Horwitz, M. E., Chute, J. P., Sullivan, K. M., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.018 · Cited by 88
“Natural killer (NK) cells may provide such benefit as they may mediate a graftversus-tumor (GVT) effect independently of aGVHD [10,11].”
Berger, M., Lanino, E., Cesaro, S., Zecca, M., Vassallo, E., Faraci, M., Bortoli, M. D., Barat, V., Prete, A., & Fagioli, F. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.02.002 · Cited by 86
“The ANC and PLT engraftments were achieved on days +17 (14-37) and +27 (16-71).”
BackgroundMethodInfluentialNK-CTLs, a novel HLA-E-restricted T-cell subset
Moretta, L., Romagnani, C., Pietra, G., Moretta, A., & Mingari, M. C. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00031-0 · Cited by 93
National marrow donor program HLA-matching guidelines for unrelated marrow transplants
Hurley, C. K., Lowe, L. A. B., Logan, B. R., Karanes, C., Anasetti, C., Weisdorf, D. J., & Confer, D. L. (2003) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.08.009 · Cited by 86
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Role of KIRs and KIR ligands in hematopoietic transplantation
Velardi, A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.07.004 · Cited by 98
Self-citationRapamycin, but not cyclosporine or FK506, alters natural killer cell function.
Wai, L., Fujiki, M., Takeda, S., Martinez, O., & Krams, S. (2008) · Transplantation · doi:10.1097/01.tp.0000296817.28053.7b · Cited by 97
Béziat, V., Hilton, H. G., Norman, P. J., & Traherne, J. A. (2016) · Immunology · doi:10.1111/imm.12684 · Cited by 90
The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity
Wallace, M. E., & Smyth, M. J. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0195-x · Cited by 95
“leagues [75] have demonstrated that BM transplantation using haploidentical, but KIR-”
BackgroundFischer, J., Ottinger, H. D., Ferenčík, S., Sribar, M., Punzel, M., Beelen, D. W., Schwan, M. A., Grosse‐Wilde, H., Wernet, P., & Uhrberg, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3918 · Cited by 84
“The C1/C2 ligand mismatch (7) was excluded from the model (RR: 1.”
BackgroundResultInfluentialUse of natural killer cells in hematopoetic stem cell transplantation
Passweg, J. R., Stern, M., Koehl, U., Uharek, L., & Tichelli, A. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704810 · Cited by 84
Human diversity of killer cell immunoglobulin-like receptors and disease
Rajalingam, R. (2011) · The Korean Journal of Hematology · doi:10.5045/kjh.2011.46.4.216 · Cited by 88
“In addition to the recipient lacking HLA class I ligands for the donor-derived NK cells, expression of activating KIR receptors on donor NK cells is also shown to influence HSCT outcome.”
BackgroundInfluentialHuman AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
Scoville, S. D., Nalin, A. P., Chen, L., Chen, L., Zhang, M. H., McConnell, K., Beceiro Casas, S., Ernst, G., Traboulsi, A. A.-R., Hashi, N., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838474 · Cited by 85
Xu, J. L., Chakrabarti, A. K., Tan, J. L., Ge, L., Gambotto, A. A., & Vujanović, N. L. (2006) · Blood · doi:10.1182/blood-2006-06-026385 · Cited by 94
Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
James, A. M., Cohen, A. D., & Campbell, K. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00481 · Cited by 90
“Velardi and colleagues first reported that donor allogenicity of NK cells in HSCT to treat acute myeloid leukemia (AML) resulted in a double benefit by enhancing antileukemia responses, while reducing graft-versus-host disease (72).”
BackgroundHuman NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Zotto, G. D., Locatelli, F., Moretta, A., & Mingari, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00087 · Cited by 99
“These studies clearly indicated that also cells of the innate immunity, such as NK cells, may guarantee a successful clinical outcome in this transplantation setting (81, 82).”
BackgroundFoley, B. A., Felices, M., Cichocki, F. M., Cooley, S., Verneris, M. R., & Miller, J. S. (2014) · Immunological Reviews · doi:10.1111/imr.12157 · Cited by 92
“The therapeutic utility of NK cell alloreactivity was first demonstrated in a 2002 study by the Perugia group (82).”
BackgroundRecent Advances in the Pathogenesis of Mucormycoses
Petrikkos, G. L., & Tsioutis, C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.009 · Cited by 97
Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells
Wang, Q.-M., Tang, P. M., Lian, G., Li, C., Li, J., Huang, X., To, K., & Lan, H. Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0491 · Cited by 84
“Indeed, immunotherapies based on cytotoxic T lymphocytes andnatural killer (NK) cells have progressed in clinical practice (4, 5).”
BackgroundNK Cell Therapy: A Rising Star in Cancer Treatment
Du, N., Guo, F., Wang, Y., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13164129 · Cited by 87
“In allogeneic NK cell infusion therapy, mismatches between inhibitory KIRs expressed on donor NK cells and recipients’ HLA ligands trigger alloreactivity of NK cells [65].”
BackgroundInduction of Tumor Immunity Following Allogeneic Stem Cell Transplantation
Wu, C. J., & Ritz, J. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90004-2 · Cited by 90
Isidori, A., Salvestrini, V., Ciciarello, M., Loscocco, F., Visani, G., Parisi, S., Lecciso, M., Očadlíková, D., Rossi, L., Gabucci, E., et al. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.958464 · Cited by 88
“Clinically, data from haploidentical T-cell depleted transplantation suggest that KIR mismatch with tumor MHC may significantly impact on tumor cell killing, particularly in AML [94].”
BackgroundÖberg, L., Johansson, S., Michaëlsson, J., Tomasello, E., Vivier, É., Kärre, K., & Höglund, P. (2004) · European Journal of Immunology · doi:10.1002/eji.200424913 · Cited by 90
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Marofi, F., Saleh, M. M., Rahman, H. S., Suksatan, W., Al-Gazally, M. E., Abdelbasset, W. K., Thangavelu, L. P., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02462-y · Cited by 90
Haploidentical stem cell transplantation for children with acute leukaemia
Marks, D. I., Khattry, N., Cummins, M., Goulden, N., Green, A. F., Harvey, J., Hunt, L. P., Keen, L. J., Robinson, S. P., Steward, C. G., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06140.x · Cited by 84
“We determined only that a KIR ligand mismatch was present in the transplant pair and identified those donor/ recipient(s) where the ligand mismatch was in the graft-versushost (GVH) or/and host-versus-graft (HVG) directions (Ruggeri et al, 2002).”
BackgroundNovel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
Brentjens, R. J., & Curran, K. J. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.143.3798224 · Cited by 93
Jitschin, R., Mougiakakos, D., Von Bahr, L., Völkl, S., Moll, G., Ringden, O., Kiessling, R., Linder, S., & Le Blanc, K. (2013) · Stem Cells · doi:10.1002/stem.1386 · Cited by 80
Pérez‐Martínez, A., Fernández, L., Valentín, J., Martínez-Romera, I., Corral, M. D., Ramírez, M. R., Abad, L., Santamaría, S., González‐Vicent, M., Sirvent, S. I., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.07.011 · Cited by 80
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials
Suen, C.-W. W., Lee, W., Leung, K. T., Pan, X., & Li, G. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1515315 · Cited by 90
“Ruggeri has shown that choosing the donor of NK cells according to patients’ KIR-ligand mismatch can provide protection against acute myeloid leukaemia (AML) relapse (47).”
BackgroundInfluentialChang, Y., Zhao, X., & Huang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03041 · Cited by 93
“(86) demonstrated, for the first time, that donor-versus-recipient NK cell alloreactivity could eliminate leukemia relapse by killing host lymphohematopoietic cells, and protect patients against GVHD by eliminating recipient-type APCs.”
BackgroundGenerating natural killer cells for adoptive transfer: expanding horizons
Kundu, S., Gurney, M. E., & O'Dwyer, M. E. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2020.12.002 · Cited by 81
Storek, J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.583 · Cited by 93
“Neutrophil engraftment may also be influenced by the number of NK cells or CD8 + T cells infused with the graft [49,60,61] .”
BackgroundAndre, M. C., Erbacher, A., Gille, C., Schmauke, V., Goecke, B., Hohberger, A., Mang, P., Kübler, A., Mueller, I., Herr, W., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000583 · Cited by 87
“immunity (2, 10, 11) in a HLA-defined situation using long-term (.”
BackgroundUllah, M. A., Hill, G. R., & Tey, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00144 · Cited by 88
“This “missing self ” NK alloreactivity can be very potent and is associated with decreased risk of relapse in T-cell-depleted haploidentical transplantation for acute myeloid leukemia (5, 6, 43).”
BackgroundBoudreau, J. E., Liu, X., Zhao, Z., Zhang, A., Shultz, L. D., Greiner, D. L., Dupont, B., & Hsu, K. C. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.005 · Cited by 80
“Reports of lower leukemia relapse rates following HLA class Imismatched HCT may be due in part to enhanced NK cell antileukemic surveillance (Ruggeri et al., 2002).”
Carapito, R., Jung, N., Kwemou, M., Untrau, M., Michel, S., Pichot, A., Giacometti, G., Macquin, C., Ilias, W., Morlon, A., et al. (2016) · Blood · doi:10.1182/blood-2016-05-719070 · Cited by 88
“Although this second possibility is theoretically feasible(43) (and, interestingly, there is a peculiar precedent for this: the murine minor histocompatibility locus, H60, encodes an MHC-I-like structure that is a NKG2D ligand(43,44)), we much favor the first option, especially given that both NK and gd T are consider…”
Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors
Oh, S., Lee, J., Kwack, K., & Choi, S.-W. (2019) · Cancers · doi:10.3390/cancers11101534 · Cited by 71
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Lamb, M. G., Rangarajan, H. G., Tullius, B. P., & Lee, D. A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02277-x · Cited by 92
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 84
Lim, O., Lee, Y., Chung, H., Her, J. H., Kang, S. M., Jung, M.-Y., Min, B., Shin, H.-J., Kim, T. M., Heo, D. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053611 · Cited by 79
“In T cell-depleted HSCT, donor NK cells are the major effector cells responsible for controlling residual cancer cells [7].”
BackgroundTha‐In, T., Metselaar, H. J., Tilanus, H. W., Groothuismink, Z. M. A., Kuipers, E. J., de Man, R. A., & Kwekkeboom, J. (2007) · Blood · doi:10.1182/blood-2007-03-077057 · Cited by 84
Hadaya, K., de Rham, C., Bandelier, C., Bandelier, C., Ferrari‐Lacraz, S., Jendly, S., Berney, T., Bühler, L. H., Kaiser, L., Seebach, J. D., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02431.x · Cited by 92
“The balance of activating and inhibitory signals is crucial in regulating NK cell effector function, and the absence or down-regulation of MHC class I expression (missing KIR ligand) can induce susceptibility of a potential target cell to NK cytotoxicity (16,17).”
BackgroundImmunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
Masouridi‐Levrat, S., Simonetta, F., & Chalandon, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00362 · Cited by 85
“In humans, a similar effect has been observed in the HLA-haploidentical setting as transplantation with KIR ligand incompatible cells in the graft-versus-host direction conferred a significant protection from graft rejection in patients with acute myeloid leukemia (36).”
ResultEx Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells
Liu, L. L., Béziat, V., Oei, V. Y. S., Pfefferle, A., Schaffer, M., Lehmann, S., Hellström‐Lindberg, E., Söderhäll, S., Heyman, M. M., Grandér, D., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0296 · Cited by 83
Human NK cells and their receptors
Moretta, L., Biassoni, R., Bottino, C., Cantoni, C., Pende, D., Mingari, M. C., & Moretta, A. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)00037-0 · Cited by 94
Negative depletion of CD3+ and TcRαβ+ T cells
Handgretinger, R. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283582340 · Cited by 83
“As it has been demonstrated in mouse models that alloreactive natural killer (NK) cells can facilitate engraftment by elimination of residual host hematopoiesis [11], thus increasing the likelihood of full donor engraftment following reduced intensity conditioning in haploidentical transplantation, attempts were made…”
BackgroundBarfield, R. C., Otto, M., Houston, J., Holladay, M. S., Geiger, T. L., Martin, J., Leimig, T., Gordon, P., Chen, X., & Handgretinger, R. (2004) · Cytotherapy · doi:10.1080/14653240310004411 · Cited by 78
Portevin, D., Poupot, M., Rolland, O., Turrin, C., Fournié, J., Majoral, J., Caminade, A., & Poupot, R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-82 · Cited by 81
“In this context, NK cell alloreactivity has been shown to increase prognosis by enhancing anti-tumor activity (GvL effect) and decrease side effects of immune reconstitution (GvHD) by depleting recipients' DCs [9,10].”
Celik, A. A., Kraemer, T. D., Huyton, T., Blasczyk, R., & Bade‐Doeding, C. (2015) · Immunogenetics · doi:10.1007/s00251-015-0880-z · Cited by 82
“However, since NK cells are one of the first lymphocytes to be reconstituted post transplantation, their involvement during GvL reactions is the subject of ongoing research (Cooley et al. 2009; Kroger et al. 2011; Ruggeri et al. 2002; Verneris 2013).”
BackgroundHuman γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias
Pistoia, V., Tumino, N., Vacca, P., Veneziani, I., Moretta, A., Locatelli, F., & Moretta, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00984 · Cited by 78
“It was proposed that γδ T-cells, recovering after the allograft, play a relevant role in the graft-versus-leukemia (GvL) (46), albeit other studies have highlighted the prominent GvL activity of NK cells in T-cell-depleted HSCT (48, 49).”
ResultHaploidentical transplantation for acute lymphoblastic leukemia in childhood
Klingebiel, T. E., Handgretinger, R., Lang, P., Bader, P., & NIETHAMMER, D. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00063-8 · Cited by 78
Trial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 86
Latency reversal plus natural killer cells diminish HIV reservoir in vivo
Kim, J. T., Zhang, T., Carmona, C., Lee, B., Seet, C. S., Kostelny, M., Shah, N. B., Chen, H., Farrell, K., Soliman, M. S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27647-0 · Cited by 86
van Bergen, J., Thompson, A., Haasnoot, G. W., Roodnat, J. I., de Fijter, J. W., Claas, F. H. J., Koning, F., & Doxiadis, I. I. N. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03621.x · Cited by 80
“In this study, we used an improved definition of KIR-ligand mismatches (5) that takes into account the requirement for the presence of the corresponding recipient KIR to detect KIR-ligand mismatches (i.e. HLA allele group differences), as well as the recent observation that NK cells can respond to ‘nonself’ C2 via the…”
BackgroundInfluentialPfeiffer, M. M., Feuchtinger, T. F., Teltschik, H., Schumm, M., Müller, I., Handgretinger, R., & Lang, P. (2010) · Haematologica · doi:10.3324/haematol.2009.021121 · Cited by 77
“Alloreactive NK cells have been demonstrated to exert remarkable graft-versus-leukemia (GvL) effects both in adult patients with acute myeloid leukemia (AML) and in pediatric patients with acute lymphoblastic leukemia (ALL).5-7 Based on these clinical findings, different models to define NK alloreactive donors have be…”
BackgroundInfluentialMicroRNA-29b mediates altered innate immune development in acute leukemia
Mundy-Bosse, B. L., Scoville, S. D., Chen, L., McConnell, K. K., Mao, H. C., Ahmed, E. H., Zorko, N. A., Harvey, S., Cole, J. P., Zhang, X., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85413 · Cited by 89
“While NK cells exhibit a potent clinical effect against AML in certain settings of T cell– depleted, haploidentical transplantation, success has not been seen in de novo AML, and immune evasion is a critical barrier to obtaining long-term disease-free survival (3, 4).”
BackgroundControl of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 86
“In the field of hematologic malignancies, haplo-identical stem cell transplantation from a KIR ligand-mismatched donor favors NK cell alloreactivity thanks to the lack of relevant KIR-HLA class I interaction [24,131].”
BackgroundNK cells: innate immunity against hematological malignancies?
Costello, R. T., Fauriat, C., Sivori, S., Marcenaro, E., & Olive, D. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.04.005 · Cited by 89
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 83
Mechanisms of Tumor and Viral Immune Escape from Natural Killer Cell-Mediated Surveillance
Groth, A., Klöß, S., von Strandmann, E. P., Koehl, U., & Koch, J. (2011) · Journal of Innate Immunity · doi:10.1159/000327014 · Cited by 95
“and possibly modify the NK cell receptor repertoire. In addition to antitumor response, a multitude of potentially beneficial effects, such as NK cells versus leukemia activity, NK cells versus residual host T cell activity and NK cells versus host dendritic cell activity with a reduced risk of graft-versus- host dise…”
Goldenson, B., Zhu, H., Wang, Y., Heragu, N., Bernareggi, D., Ruiz-Cisneros, A., Bahena, A., Ask, E. H., Hoel, H. J., Malmberg, K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561553 · Cited by 67
Merino, A. M., Maakaron, J. E., & Bachanová, V. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101073 · Cited by 80
REVIEW ARTICLE: NK Cell Tolerance and the Maternal–Fetal Interface
Riley, J. K., & Yokoyama, W. M. (2008) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2008.00593.x · Cited by 78
Moretta, A., Pende, D., Locatelli, F., & Moretta, L. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03983.x · Cited by 83
Nakamura, R., Nademanee, A. P., Smith, D. D., Palmer, J. M., Sun, J. Y., Schriber, J. R., Pullarkat, V. A., Parker, P. A., Rodríguez, R., Stein, A. S., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.005 · Cited by 76
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy
Luevano, M., Madrigal, J. A., & Saudemont, A. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.17 · Cited by 86
Li, H., Demetris, A. J., McNiff, J. M., Matte-Martone, C. C., Tan, H. S., Rothstein, D. M., Lakkis, F. G., & Shlomchik, W. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102795 · Cited by 81
“Host hematopoietic cells were also required for lethal GVHD in the BALB/c (H-2)→B6 (H-2) MHCmismatched strain pairing (7).”
BackgroundSelf-citationPurification of human natural killer cells using a clinical-scale immunomagnetic method
Iyengar, R. V., Handgretinger, R., Babarin-Dorner, A., Leimig, T., Otto, M., Geiger, T. L., Holladay, M. S., Houston, J., & Leung, W. H. (2003) · Cytotherapy · doi:10.1080/14653240310003558 · Cited by 76
Baessler, T., Krusch, M., Schmiedel, B. J., Kloss, M., Baltz, K. M., Wacker, A., Schmetzer, H. M., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2650 · Cited by 84
“Clinical evidence for the particularly important role of NK cells in leukemia has been provided by studies of haploidentical stem cell transplantation (SCT), wherein recipient’s leukemia cells fail to inhibit donor NK cells via KIR receptors, and KIR disparity has been shown to be associated with powerful graft versus…”
Natural Killer Cell Memory: Progress and Implications
Peng, H., & Tian, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01143 · Cited by 75
The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation
Riddell, S. R., Berger, C., Murata, M., Randolph, S., & Warren, E. H. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00007-9 · Cited by 76
Immunotherapeutic strategies for relapse control in acute myeloid leukemia
Martner, A., Thorén, F. B., Aurelius, J., & Hellstrand, K. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.006 · Cited by 79
“HLA class I molecules of the recipient thus revealed thatmismatches of KIR/class I –which predict allo-reactivity of grafted NK cells – were strongly associated with a reduced risk of relapse after allo-transplantation [49].”
BackgroundRoberto, A., di Vito, C., Zaghi, E., Mazza, E., Capucetti, A., Calvi, M., Tentorio, P., Zanon, V., Sarina, B., Mariotti, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.186619 · Cited by 71
“These findings confirmed that donor-derived NK cells represent the first lymphoid compartment to immune-reconstitute in allogeneic HSCT prior to T and B cells.(6,7,21,22,24,25) We then characterized the dynamic of circulating NK cell subset IR early after hHSCT.”
BackgroundNK Cell-Based Glioblastoma Immunotherapy
Golán, I., de la Fuente, L. R., & Costoya, J. A. (2018) · Cancers · doi:10.3390/cancers10120522 · Cited by 81
“This approach results in a lack of recognition of tumor MHC molecules by the KIRs present on the allogeneic NKs and, as consequent, there is an absence of inhibitory signals allowing NK cells activation [39,64].”
BackgroundUmbilical Cord Blood Transplants: Current Status and Evolving Therapies
Gupta, A. O., & Wagner, J. E. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.570282 · Cited by 80
Gaggero, S., Witt, K., Carlsten, M., & Mitra, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621225 · Cited by 85
“Experimental approaches delineating how NK cells target tumor cells have in more recent years been harmonized with studies evidencing their role in tumor immune surveillance (3) and clinical therapy to treat patients with cancer (4, 5).”
BackgroundPierini, A., Ruggeri, L., Carotti, A., Falzetti, F., Saldi, S., Terenzi, A., Zucchetti, C., Ingrosso, G., Zei, T., Ostini, R. I., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003739 · Cited by 75
“Donors with HLA disparities that allowed donor-versus-recipient NK cell alloreactivity were preferred.(13) In the absence of NK cell alloreactivity, maternal donors were preferred.”
BackgroundSelf-citation
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.